← Back to Search

Apneic Oxygenation for Neonatal Respiratory Failure (POINT Trial)

N/A
Recruiting
Led By Elizabeth Foglia, MD, MSCE
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 18 months.
Awards & highlights
No Placebo-Only Group

Summary

This trial will compare apneic oxygenation to standard care in order to determine if apneic oxygenation reduces oxygen desaturation during tracheal intubation in infants in the NICU.

Who is the study for?
This trial is for infants at least 28 weeks corrected gestational age who need a breathing tube inserted in the NICU and have received pre-medication. It's not for babies previously enrolled, with certain health conditions like unstable blood pressure, specific heart or lung problems, COVID-19, or those intubated by non-NICU providers.
What is being tested?
The study tests if giving oxygen through the nose (apneic oxygenation) to babies who can't breathe on their own during intubation is better than the usual method without extra oxygen. Infants are randomly chosen to receive either apneic oxygenation or standard care at two hospitals.
What are the potential side effects?
While there may be minimal side effects directly from apneic oxygenation itself, potential risks include discomfort from the nasal cannula and possible impact on delicate tissues due to increased airflow.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 18 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 18 months. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Primary Clinical Outcome: Change in Oxygen Saturation (SpO2)
Secondary study objectives
Feasibility Outcome: AO fidelity
Feasibility Outcome: Protocol deviations
Feasibility Outcome: Randomization
+12 more
Other study objectives
Safety Outcome: Air Leaks
Safety Outcome: Cardiopulmonary resuscitation
Safety Outcome: Duration of time with 100% SpO2
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Apneic OxygenationExperimental Treatment1 Intervention
Group II: Standard of CareActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Apneic Oxygenation
2017
N/A
~200

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
2,084 Previous Clinical Trials
42,726,423 Total Patients Enrolled
Children's Hospital of PhiladelphiaOTHER
731 Previous Clinical Trials
8,472,209 Total Patients Enrolled
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
2,068 Previous Clinical Trials
2,747,597 Total Patients Enrolled
Elizabeth Foglia, MD, MSCEPrincipal InvestigatorUniversity of Pennsylvania

Media Library

Apneic Oxygenation Clinical Trial Eligibility Overview. Trial Name: NCT05451953 — N/A
Tracheal Intubation Morbidity Research Study Groups: Apneic Oxygenation, Standard of Care
Tracheal Intubation Morbidity Clinical Trial 2023: Apneic Oxygenation Highlights & Side Effects. Trial Name: NCT05451953 — N/A
Apneic Oxygenation 2023 Treatment Timeline for Medical Study. Trial Name: NCT05451953 — N/A
~4 spots leftby Jan 2025